Ocular Pain - Pipeline Review, H1 2016

Date: March 22, 2016
Pages: 70
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OACB2EECFFEEN
Leaflet:

Download PDF Leaflet

Ocular Pain - Pipeline Review, H1 2016
Ocular Pain - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Ocular Pain - Pipeline Review, H1 2016’, provides an overview of the Ocular Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ocular Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Ocular Pain
  • The report reviews pipeline therapeutics for Ocular Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ocular Pain therapeutics and enlists all their major and minor projects
  • The report assesses Ocular Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ocular Pain
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ocular Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Ocular Pain Overview
Therapeutics Development
Pipeline Products for Ocular Pain - Overview
Ocular Pain - Therapeutics under Development by Companies
Ocular Pain - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Ocular Pain - Products under Development by Companies
Ocular Pain - Companies Involved in Therapeutics Development
InSite Vision Incorporated
Kala Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Reata Pharmaceuticals, Inc.
Sylentis S.A.U.
Valeant Pharmaceuticals International, Inc.
Ocular Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(bromfenac sodium + dexamethasone acetate) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone acetate SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
difluprednate XR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISV-303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ketorolac tromethamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
loteprednol etabonate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
loteprednol etabonate next generation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NT-71 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NT-72 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
omaveloxolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RX-10045 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Block NaV1.7 Channel for Pain and Pruritus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYL-1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ocular Pain - Recent Pipeline Updates
Ocular Pain - Dormant Projects
Ocular Pain - Product Development Milestones
Featured News & Press Releases
Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome
Jan 11, 2016: Ocular Therapeutix Strengthens Executive Management Team with the Appointment of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., as Chief Medical Officer
Dec 09, 2015: Ocular Therapeutix Announces FDA Acceptance of NDA Filing for DEXTENZA for the Treatment of Post-Surgical Ocular Pain
Oct 14, 2015: Ocular Therapeutix Begins Enrollment in Third Phase 3 Clinical Trial for DEXTENZA for the Treatment of Post-Surgical Ocular Inflammation and Pain
Sep 02, 2015: InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit
Aug 17, 2015: InSite Vision Announces FDA Acceptance of NDA Filing for BromSite
May 15, 2015: Ocular Therapeutix Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication
Oct 01, 2013: Ocular Therapeutix Announces Phase 2 Study Results for Sustained Release Dexamethasone
Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery
May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Ocular Pain, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Ocular Pain - Pipeline by InSite Vision Incorporated, H1 2016
Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H1 2016
Ocular Pain - Pipeline by Ocular Therapeutix, Inc., H1 2016
Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H1 2016
Ocular Pain - Pipeline by Sylentis S.A.U., H1 2016
Ocular Pain - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Ocular Pain Therapeutics - Recent Pipeline Updates, H1 2016
Ocular Pain - Dormant Projects, H1 2016

LIST OF FIGURES

Number of Products under Development for Ocular Pain, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016
Skip to top


Ocular Pain - Pipeline Review, Q2 2011 US$ 500.00 May, 2011 · 32 pages
Ocular Inflammation - Pipeline Review, Q1 2011 US$ 500.00 Mar, 2011 · 45 pages
Osteoarthritis Pain - Pipeline Review, H2 2015 US$ 2,000.00 Oct, 2015 · 190 pages
Acute Pain - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 194 pages
Ocular Inflammation - Pipeline Review, Q4 2010 US$ 500.00 Nov, 2010 · 50 pages

Ask Your Question

Ocular Pain - Pipeline Review, H1 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: